Arsenal Medical

Executive Summary

Arsenal Medical is a private medical device and drug delivery company headquartered in Watertown, Massachusetts, that specializes in developing breakthrough biomaterial-based technologies for hemorrhage control and vascular occlusion. Founded in 2005, the company focuses on addressing unmet clinical needs in neurovascular conditions and traumatic injury by transforming medical devices with innovative materials. Its platform has the potential to significantly improve patient outcomes in emergency and surgical settings, where rapid and effective bleeding control is critical. Despite being private and relatively low-profile, Arsenal Medical's technology addresses large and growing markets, including trauma care and neurovascular intervention. The company is likely in the clinical development stage, with its most advanced products targeting regulatory clearance. Key upcoming value drivers include the initiation of pivotal trials, FDA submissions, and potential partnership announcements. The company's innovative biomaterial platform and experienced team position it well for success, though execution and regulatory risks remain.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Pivotal Clinical Trial for Neurovascular Occlusion Device60% success
• Q4 2026FDA 510(k) Submission for Hemorrhage Control Product50% success
• Q2 2026First-in-Human Study Results for Novel Biomaterial Platform40% success